1641P - Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)

M.M Laterza,V Ciaramella,F Morgillo,V Belli,G Tirino,L Pompella,A Petrillo,B Savastano,A Pappalardo,M Orditura,F Ciardiello,F De Vita

doi:10.1093/annonc/mdx390.013

1641P - Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)

M.M Laterza, V Ciaramella + Show 10 more

Open Access

https://doi.org/10.1093/annonc/mdx390.013

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2017
License type: elsevier-specific: oa user license

Affiliation: University of Campania "Luigi Vanvitelli"

#HER2 Positive Gastric Cancer Cells #Anti HER3 Antibody + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1641P - Combination of duligotuzumab, anti HER3 antibody or taselisib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)

Full Text